A winning war against hepatitis B virus infection in China

Chinese Medical Journal

Volumn 120, Issue 24, 2007, Pages 2157-2158

  Jia, Ji Dong ^a   Zhuang, Hui ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA2A; TELBIVUDINE;

AMINOTRANSFERASE BLOOD LEVEL; CHILD CARE; CHINA; CLINICAL TRIAL; EDITORIAL; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; INCIDENCE; INFECTION RISK; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; URBAN RURAL DIFFERENCE; VACCINATION; VIRUS CARRIER; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 38349086657     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200712020-00001     Document Type: Editorial

References (14)

1. World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 dex. (Accessed on October 2000 at http:www.who.int/ mediacentre/factsheets/fs204/en.htm)
2. Dai ZC, Qi GM. Viral hepatitis in China: Seroepidemiological survey in Chinese population (Part one). Beijing Science and Technology Press; 1997: 39-58.
3. Ministry of Public Health. Chinese Health Statistical Digest 2007. (Accessed on November 19, 2007 at http//www.moh.gov.cn/open/2007/ P44.htm)
4. Zhu X, Zhang XL, Wang LX. National EPI vaccination and hepatitis B coverage rate and the related factors: results from the 1999 national coverage survey. Chin J Vac Immun (Chin) 2000; 6: 1-5.
5. Xia GL, Liu CB, Yan TQ, Ma JC, Yang JY, Liu YX, et al. Prevalence of hepatitis B virus markers in children vaccinated by hepatitis B vaccine in five areas of China. Chin J Exp Clin Virol (Chin) 1995; 9 (Suppl): 17-23.
6. Li H, Li RC, Liao SS, Yang JY, Zeng XJ, Gong J, et al. Long-term persistence of immunological memory for HBsAg after initial hepatitis B vaccine immunoprophylaxis. Chin Med Sci J (Chin) 1999; 14 (Suppl): 17-20.
7. Li RC, Yang JY, Wang SS, Gong J, Li YP, Nong Y, et al. 10 year follow-up on hepatitis B virus markers in the population after hepatitis B vaccination. Chin J Exp Clin Virol (Chin) 1995; 9 (Suppl): 32-36.
8. Liang XF, Chen YS, Wang XJ, He X, Chen LJ, Wang J, et al. A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old. Chin J Epidemiol (Chin) 2005; 26: 655-658.
9. Yao G, Wang B, Cui Z, Yao J, Zeng M. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Chin Med J 1999; 112: 387-391.
10. Zeng M, Mao Y, Yao G, Wang H, Hou J, Wang Y, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006; 44: 108-116.
11. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695.
12. Hou JL, Yin YK, Xu DZ, Tan DM, Niu JQ. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2007; In press.
13. Chinese Society of Hepatology and Chinese Society of Infectious Diseases. Guideline on the prevention and treatment of chronic hepatitis B. Chin J Hepatol (Chin) 2005; 13: 881-891.
14. Chinese Society of Hepatology, Chinese Medical Association and Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline on the prevention and treatment of chronic hepatitis B in China (2005). Chin Med J 2007; 120: 2159-2173.